To scrutinize further the methylation changes related to gene defects commonly detected in CH and hematological malignancies1, and to provide additional context to findings in TET2 mutation carriers, we derived targeted bisulfite sequencing data from blood DNA of four DNMT3A germline mutation carriers and their age-matched controls from the NFID Cohort (Supplementary Table 3). Here, TET2 is linked to cyclic hematopoiesis.